Subgroup analysis showed a pooled PSMA detection rate of 0.74 (95% CI, 0.57–0.86) in staging or evaluation of primary RCC lesions and 0.87 (95% CI, 0.73–0.95) in restaging of metastatic or recurrent RCC. The gene discussed is FOLH1; the disease is renal cell carcinoma.